Changes in Hong Kong stocks | Giant Biotech (02367) can fall more than 3%, but the US can recover under pressure in the short term, and many institutions will lower their performance forecasts

The Zhitong Finance App learned that Giant Biotech (02367) fell by more than 3%. As of press release, it was down 2.93% to HK$35.14, with a turnover of HK$236 million.

According to news, Juzi Biotech's sales were under pressure during the Double Eleven period. According to management data, sales of the Comfy brand on Tmall and Douyin fell 20% and 50% year-on-year, respectively. CMB International released a research report saying that due to short-term pressure from the US, the bank lowered the company's 2025/26 revenue forecast to -3.5% and 13.6%. According to the report, during the “Double Eleven” period, the company's sales were under pressure, mainly due to Dabo's sales performance falling short of expectations.

CITIC Securities released a research report saying that due to the influence of the industry environment and trade-offs in corporate operation decisions, Gizi Biotech's Double Eleven sales were under pressure and lowered revenue and profit forecasts for 2025. At the same time, the company's brand assets are solid, and there are structural highlights in operations. Looking forward to the future, the company has clear ideas for the short, medium and long term. Fumei can set a revenue target of 10 billion dollars and formulate clear plans in terms of product/operation/channels. Clekin will carry out brand reshaping at the same time as promoting new products, and can be expected to build a second popular OTC brand.